董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Kevin O'Boyle | 男 | Director | 70 | 未披露 | 未持股 | 2026-01-09 |
| Karen Prange | 女 | Director | 62 | 未披露 | 未持股 | 2026-01-09 |
| Leslie Trigg | 女 | President, Chief Executive Officer and Chair of the Board | 55 | 69.01万美元 | 未持股 | 2026-01-09 |
| Patrick T. Hackett | 男 | Director | 64 | 未披露 | 未持股 | 2026-01-09 |
| Brent D. Lang | 男 | Director | 58 | 未披露 | 未持股 | 2026-01-09 |
| D. Keith Grossman | 男 | Lead Independent Director | 65 | 10.00万美元 | 未持股 | 2026-01-09 |
| Karen Drexler | 女 | Director | 65 | 未披露 | 未持股 | 2026-01-09 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Leslie Trigg | 女 | President, Chief Executive Officer and Chair of the Board | 55 | 69.01万美元 | 未持股 | 2026-01-09 |
| John L. Brottem | 男 | General Counsel and Secretary | 53 | 未披露 | 未持股 | 2026-01-09 |
| Renee Gaeta | 女 | Chief Financial Officer and Principal Accounting Officer | 45 | 未披露 | 未持股 | 2026-01-09 |
| Marc Nash | 男 | Senior Vice President, Operations and R&D | 36 | 未披露 | 未持股 | 2026-01-09 |
| Renee Gaeta | 女 | Chief Financial Officer and Principal Accounting Officer | 44 | 未披露 | 未持股 | 2026-01-09 |
董事简历
中英对照 | 中文 | 英文- Kevin O'Boyle
-
Kevin O'Boyle，他是公司的董事（2014年7月以来）。从2010年12月到2011年7月，他曾担任Advanced BioHealing公司的高级副总裁兼首席财务官，直到公司被Shire公司收购。从2003年初到2009年9月，他曾担任NuVasive公司的首席财务官。他目前担任GenMark Diagnostics公司、Durata Therapeutics公司、Tornier公司、Zeltiq Aesthetics公司的董事。他持有Rochester Institute of Technology的会计学士学位，以及加州大学洛杉矶分校安德森商学院（UCLA Anderson School of Management）的执行管理项目。
Kevin O'Boyle,has served as a member of Board of Directors since September 2024. Mr. O'Boyle has over 20 years of executive management experience in the medical device industry. Mr. O'Boyle previously served on the boards of Nevro, Inc., from March 2019 until it was acquired in April 2025, where he was the chair of the audit committee; Sientra, Inc., from May 2014 to June 2023, where he was the chair of the audit committee and a member of the nominating and corporate governance committee; GenMark Diagnostics, Inc. from, February 2010 until it was acquired in April 2021, where he was chairman of the board and the chair of the audit committee, and Wright Medical Group N.V., from November 2015 until it was acquired in November 2020, where he was the chair of the audit committee. Mr. O'Boyle received a B.S. in accounting from the Rochester Institute of Technology and completed the Executive Program at the University of California Los Angeles, Anderson School of Management. - Kevin O'Boyle，他是公司的董事（2014年7月以来）。从2010年12月到2011年7月，他曾担任Advanced BioHealing公司的高级副总裁兼首席财务官，直到公司被Shire公司收购。从2003年初到2009年9月，他曾担任NuVasive公司的首席财务官。他目前担任GenMark Diagnostics公司、Durata Therapeutics公司、Tornier公司、Zeltiq Aesthetics公司的董事。他持有Rochester Institute of Technology的会计学士学位，以及加州大学洛杉矶分校安德森商学院（UCLA Anderson School of Management）的执行管理项目。
- Kevin O'Boyle,has served as a member of Board of Directors since September 2024. Mr. O'Boyle has over 20 years of executive management experience in the medical device industry. Mr. O'Boyle previously served on the boards of Nevro, Inc., from March 2019 until it was acquired in April 2025, where he was the chair of the audit committee; Sientra, Inc., from May 2014 to June 2023, where he was the chair of the audit committee and a member of the nominating and corporate governance committee; GenMark Diagnostics, Inc. from, February 2010 until it was acquired in April 2021, where he was chairman of the board and the chair of the audit committee, and Wright Medical Group N.V., from November 2015 until it was acquired in November 2020, where he was the chair of the audit committee. Mr. O'Boyle received a B.S. in accounting from the Rochester Institute of Technology and completed the Executive Program at the University of California Los Angeles, Anderson School of Management.
- Karen Prange
-
Karen Prange自2016年起担任全球动物健康，医疗和牙科外科集团执行副总裁兼首席执行官。在加入之前，Prange女士自2012年起担任波士顿科学公司高级副总裁兼泌尿科和骨盆健康总裁并担任强生公司负责人的各种职务，最近担任Micrus Endovascular和Codman Neurovascular业务的总经理。 Prange女士是200 C200委员会的成员，该委员会是世界上最成功的女企业家和企业创新者的会员组织。
Karen Prange,has served on the board of directors of Atricure, Inc., a medical device company, since December 2019, and on the board of directors of Embecta Corp., a medical device and technology company, since April 2022. She also currently serves on the board of directors of WS Audiology, a privately held medical device company, and has served as a Senior Advisor at EQT Group, a global investment organization, since March 2020. In her most recent operating role, Ms. Prange was Executive Vice President and Chief Executive Officer for the Global Animal Health, Medical and Dental Surgical Group at Henry Schein, Inc., and a member of its Executive Committee, from May 2016 to April 2018. Prior to that, she was Senior Vice President of Boston Scientific and President of its Urology and Pelvic Health business from June 2012 to May 2016. Earlier in her career, Ms. Prange held various leadership positions at Johnson & Johnson, including sales, marketing, market development and general management roles. She also previously served on the boards of directors of several medical device companies: Nevro Corp. (acquired by Globus Medical, Inc.) from December 2019 to April 2025; ViewRay, Inc. from June 2021 to October 2023; and Cantel Medical Corporation (acquired by STERIS plc) from October 2019 to June 2021. Ms. Prange holds a B.S. from the University of Florida. - Karen Prange自2016年起担任全球动物健康，医疗和牙科外科集团执行副总裁兼首席执行官。在加入之前，Prange女士自2012年起担任波士顿科学公司高级副总裁兼泌尿科和骨盆健康总裁并担任强生公司负责人的各种职务，最近担任Micrus Endovascular和Codman Neurovascular业务的总经理。 Prange女士是200 C200委员会的成员，该委员会是世界上最成功的女企业家和企业创新者的会员组织。
- Karen Prange,has served on the board of directors of Atricure, Inc., a medical device company, since December 2019, and on the board of directors of Embecta Corp., a medical device and technology company, since April 2022. She also currently serves on the board of directors of WS Audiology, a privately held medical device company, and has served as a Senior Advisor at EQT Group, a global investment organization, since March 2020. In her most recent operating role, Ms. Prange was Executive Vice President and Chief Executive Officer for the Global Animal Health, Medical and Dental Surgical Group at Henry Schein, Inc., and a member of its Executive Committee, from May 2016 to April 2018. Prior to that, she was Senior Vice President of Boston Scientific and President of its Urology and Pelvic Health business from June 2012 to May 2016. Earlier in her career, Ms. Prange held various leadership positions at Johnson & Johnson, including sales, marketing, market development and general management roles. She also previously served on the boards of directors of several medical device companies: Nevro Corp. (acquired by Globus Medical, Inc.) from December 2019 to April 2025; ViewRay, Inc. from June 2021 to October 2023; and Cantel Medical Corporation (acquired by STERIS plc) from October 2019 to June 2021. Ms. Prange holds a B.S. from the University of Florida.
- Leslie Trigg
-
Leslie Trigg已经同意在我们的董事会任职。Trigg女士自2014年11月起担任Except Medical Inc.“；Except”；（NASDAQ:OM）的总裁兼首席执行官。从2012年3月到2014年3月，她加入Warburg Pincus公司（私人股本公司），在那里她曾担任高级管理人员。在此之前，2010年1月至2012年2月，特里格曾在医疗设备公司Lutonix（被CR Bard收购）担任多个职位，最近的职位是担任执行Vice President，并担任医疗设备公司AccessClosure（被Cardinal Health收购）的首席商务官，从2006年9月到2009年6月。她此前也曾担任FoxHollow Technologies公司（被EV3/Covidien公司收购）（治疗外周动脉疾病的设备制造商）、Cytyc公司（诊断和医疗设备公司）、Pro-Ducture Health公司（被Cytyc公司收购）（医疗设备公司）、Guidant公司（心血管医疗设备公司）的职务。Trigg女士拥有西北大学（Northwestern University）的学士学位和加州大学伯克利分校哈斯商学院（Haas School of Business，UC Berkeley）的工商管理硕士学位。
Leslie Trigg,has served as President and CEO and a member of Board since November 2014 and as Chair of Board since February 2022. Ms. Trigg joined the Company from Warburg Pincus, a private equity firm, where she was an Executive in Residence from March 2012 to March 2014. Prior to that, Ms. Trigg served in several roles at Lutonix (acquired by CR Bard), a medical device company, from January 2010 to February 2012, most recently as Executive Vice President, and as Chief Business Officer of AccessClosure (acquired by Cardinal Health), a medical device company, from September 2006 to June 2009. She also previously held positions with FoxHollow Technologies (acquired by ev3/Covidien), a manufacturer of devices to treat peripheral artery disease, Cytyc, a diagnostic and medical device company, Pro-Duct Health (acquired by Cytyc), a medical device company, and Guidant, a cardiovascular medical device company. Ms. Trigg also serves as the Chair of the board of directors of the Medical Device Manufacturers Association (MDMA). Previously, Ms. Trigg served on the boards of directors of Adaptive Biotechnologies Corporation, a biotechnology company, from March 2021 to June 2023, and of ARYA Sciences Acquisition Corp IV, a special purpose acquisition company, from March 2021 to July 2024. Ms. Trigg holds a B.S. degree from Northwestern University and an M.B.A. from The Haas School of Business, University of California, Berkeley. - Leslie Trigg已经同意在我们的董事会任职。Trigg女士自2014年11月起担任Except Medical Inc.“；Except”；（NASDAQ:OM）的总裁兼首席执行官。从2012年3月到2014年3月，她加入Warburg Pincus公司（私人股本公司），在那里她曾担任高级管理人员。在此之前，2010年1月至2012年2月，特里格曾在医疗设备公司Lutonix（被CR Bard收购）担任多个职位，最近的职位是担任执行Vice President，并担任医疗设备公司AccessClosure（被Cardinal Health收购）的首席商务官，从2006年9月到2009年6月。她此前也曾担任FoxHollow Technologies公司（被EV3/Covidien公司收购）（治疗外周动脉疾病的设备制造商）、Cytyc公司（诊断和医疗设备公司）、Pro-Ducture Health公司（被Cytyc公司收购）（医疗设备公司）、Guidant公司（心血管医疗设备公司）的职务。Trigg女士拥有西北大学（Northwestern University）的学士学位和加州大学伯克利分校哈斯商学院（Haas School of Business，UC Berkeley）的工商管理硕士学位。
- Leslie Trigg,has served as President and CEO and a member of Board since November 2014 and as Chair of Board since February 2022. Ms. Trigg joined the Company from Warburg Pincus, a private equity firm, where she was an Executive in Residence from March 2012 to March 2014. Prior to that, Ms. Trigg served in several roles at Lutonix (acquired by CR Bard), a medical device company, from January 2010 to February 2012, most recently as Executive Vice President, and as Chief Business Officer of AccessClosure (acquired by Cardinal Health), a medical device company, from September 2006 to June 2009. She also previously held positions with FoxHollow Technologies (acquired by ev3/Covidien), a manufacturer of devices to treat peripheral artery disease, Cytyc, a diagnostic and medical device company, Pro-Duct Health (acquired by Cytyc), a medical device company, and Guidant, a cardiovascular medical device company. Ms. Trigg also serves as the Chair of the board of directors of the Medical Device Manufacturers Association (MDMA). Previously, Ms. Trigg served on the boards of directors of Adaptive Biotechnologies Corporation, a biotechnology company, from March 2021 to June 2023, and of ARYA Sciences Acquisition Corp IV, a special purpose acquisition company, from March 2021 to July 2024. Ms. Trigg holds a B.S. degree from Northwestern University and an M.B.A. from The Haas School of Business, University of California, Berkeley.
- Patrick T. Hackett
-
Patrick T. Hackett于2019年5月起在Outset Medical董事会任职。Hackett先生自2017年1月起担任医疗保健私营软件公司Intelligent Medical Objects的董事会成员。此前，Hackett曾于1990年6月至2017年7月在私人股本公司Warburg Pincus担任董事总经理。他之前曾在私人商业银行合伙企业Cove Capital Associates、私人股本公司Acadia Partners以及投资银行Donaldson，Lufkin和Jenrette任职。自2016年5月以来，Hackett一直担任Connecticut一家非营利性社区医院斯坦福医疗系统的董事会成员。2008年2月至2017年11月，他还担任中学后教育服务提供商Bridgepoint Education的董事会成员；2008年1月至2015年10月，Yodlee被数据聚合和数据分析平台公司Envestnet收购；2009年1月至2014年9月，语音和语言软件提供商Nuance Communications。Hackett先生还曾在多家私营公司的董事会任职。Hackett先生拥有宾夕法尼亚大学的学士学位和宾夕法尼亚大学沃顿商学院的学士学位。
Patrick T. Hackett,has served on Board since May 2019. Mr. Hackett has served on the board of directors of Intelligent Medical Objects, a private healthcare software company, since January 2017. Previously, Mr. Hackett served as a Managing Director at Warburg Pincus, a private equity firm, from June 1990 to July 2017, where he focused on investments in the technology and healthcare services fields across the firm's global territories, and he currently serves as a senior advisor to Warburg Pincus. He previously held positions with Cove Capital Associates, a private merchant banking partnership, Acadia Partners, a private equity firm, and Donaldson, Lufkin and Jenrette, an investment bank. Mr. Hackett served on the board of directors of Stamford Health System, a nonprofit community hospital in Connecticut, from May 2016 to September 2024, including as its Chair from October 2020 to September 2022. He also served on the board of directors of Bridgepoint Education, a provider of post-secondary education services, from February 2008 to November 2017; Yodlee (acquired by Envestnet), a data aggregation and data analytics platform company, from January 2008 to October 2015; and Nuance Communications (acquired by Microsoft), a provider of voice and language software, from January 2009 to September 2014. Mr. Hackett has also served on the board of directors of a number of private companies. Mr. Hackett holds a B.A. from the University of Pennsylvania and a B.S. from The Wharton School, University of Pennsylvania. - Patrick T. Hackett于2019年5月起在Outset Medical董事会任职。Hackett先生自2017年1月起担任医疗保健私营软件公司Intelligent Medical Objects的董事会成员。此前，Hackett曾于1990年6月至2017年7月在私人股本公司Warburg Pincus担任董事总经理。他之前曾在私人商业银行合伙企业Cove Capital Associates、私人股本公司Acadia Partners以及投资银行Donaldson，Lufkin和Jenrette任职。自2016年5月以来，Hackett一直担任Connecticut一家非营利性社区医院斯坦福医疗系统的董事会成员。2008年2月至2017年11月，他还担任中学后教育服务提供商Bridgepoint Education的董事会成员；2008年1月至2015年10月，Yodlee被数据聚合和数据分析平台公司Envestnet收购；2009年1月至2014年9月，语音和语言软件提供商Nuance Communications。Hackett先生还曾在多家私营公司的董事会任职。Hackett先生拥有宾夕法尼亚大学的学士学位和宾夕法尼亚大学沃顿商学院的学士学位。
- Patrick T. Hackett,has served on Board since May 2019. Mr. Hackett has served on the board of directors of Intelligent Medical Objects, a private healthcare software company, since January 2017. Previously, Mr. Hackett served as a Managing Director at Warburg Pincus, a private equity firm, from June 1990 to July 2017, where he focused on investments in the technology and healthcare services fields across the firm's global territories, and he currently serves as a senior advisor to Warburg Pincus. He previously held positions with Cove Capital Associates, a private merchant banking partnership, Acadia Partners, a private equity firm, and Donaldson, Lufkin and Jenrette, an investment bank. Mr. Hackett served on the board of directors of Stamford Health System, a nonprofit community hospital in Connecticut, from May 2016 to September 2024, including as its Chair from October 2020 to September 2022. He also served on the board of directors of Bridgepoint Education, a provider of post-secondary education services, from February 2008 to November 2017; Yodlee (acquired by Envestnet), a data aggregation and data analytics platform company, from January 2008 to October 2015; and Nuance Communications (acquired by Microsoft), a provider of voice and language software, from January 2009 to September 2014. Mr. Hackett has also served on the board of directors of a number of private companies. Mr. Hackett holds a B.A. from the University of Pennsylvania and a B.S. from The Wharton School, University of Pennsylvania.
- Brent D. Lang
-
Brent D. Lang，自2013年6月起担任总裁兼首席执行官并担任董事会成员。2007年10月至2013年6月，他担任总裁兼首席运营官。2007年2月至2007年10月担任执行副总裁，2007年1月至2007年6月担任代理首席执行官，2001年6月至2007年1月担任市场营销和业务发展副总裁。从1995年9月至2001年6月，Lang先生曾任职于3Com Corporation，这是一家网络公司，在该公司担任过多种职务，包括负责3Com数字家庭产品的高级营销总监。1991年6月至1993年6月，Lang先生在咨询公司Monitor Company，Inc.担任战略顾问，为《财富》500强企业提供咨询服务。Lang先生获得了Michigan大学工业与运营工程学士学位和Stanford大学商学院工商管理硕士学位。
Brent D. Lang has served as President and Chief Executive Officer and on Board of Directors since June 2013. From October 2007 to June 2013 he served as President and Chief Operating Officer. From February 2007 to October 2007 he served as Executive Vice President,from January 2007 to June 2007 he served as Acting Chief Executive Officer,and from June 2001 through January 2007 he served as Vice President of Marketing and Business Development. From September 1995 to June 2001 Mr. Lang worked for 3Com Corporation,a networking company, where he served in a variety of roles including senior director of marketing responsible for 3Com's digital home products. From June 1991 to June 1993 Mr. Lang worked as a strategy consultant for Monitor Company,Inc.,a consulting firm,advising Fortune 500 companies. Mr. Lang earned a B.S. degree in Industrial and Operations Engineering from the University of Michigan and an M.B.A. degree from the Stanford University Graduate School of Business. - Brent D. Lang，自2013年6月起担任总裁兼首席执行官并担任董事会成员。2007年10月至2013年6月，他担任总裁兼首席运营官。2007年2月至2007年10月担任执行副总裁，2007年1月至2007年6月担任代理首席执行官，2001年6月至2007年1月担任市场营销和业务发展副总裁。从1995年9月至2001年6月，Lang先生曾任职于3Com Corporation，这是一家网络公司，在该公司担任过多种职务，包括负责3Com数字家庭产品的高级营销总监。1991年6月至1993年6月，Lang先生在咨询公司Monitor Company，Inc.担任战略顾问，为《财富》500强企业提供咨询服务。Lang先生获得了Michigan大学工业与运营工程学士学位和Stanford大学商学院工商管理硕士学位。
- Brent D. Lang has served as President and Chief Executive Officer and on Board of Directors since June 2013. From October 2007 to June 2013 he served as President and Chief Operating Officer. From February 2007 to October 2007 he served as Executive Vice President,from January 2007 to June 2007 he served as Acting Chief Executive Officer,and from June 2001 through January 2007 he served as Vice President of Marketing and Business Development. From September 1995 to June 2001 Mr. Lang worked for 3Com Corporation,a networking company, where he served in a variety of roles including senior director of marketing responsible for 3Com's digital home products. From June 1991 to June 1993 Mr. Lang worked as a strategy consultant for Monitor Company,Inc.,a consulting firm,advising Fortune 500 companies. Mr. Lang earned a B.S. degree in Industrial and Operations Engineering from the University of Michigan and an M.B.A. degree from the Stanford University Graduate School of Business.
- D. Keith Grossman
-
D. Keith Grossman，在医疗器械和用品领域拥有超过35年的经验，包括担任医疗保健上市公司的首席执行官。他自2019年3月起担任Nevro的董事长、首席执行官兼总裁。他还自2014年起担任Outset Medical董事会主席。他于1996年至2006年以及2014年至2015年担任Thoratec Corporation的总裁兼首席执行官，并于1996年至2015年担任董事会成员。Grossman先生曾于2011年至2013年担任Conceptus公司的首席执行官和董事会成员。2007年至2011年担任TPG资本有限公司董事总经理兼高级顾问。Grossman先生还曾于2018年至2021年担任ViewRay，Inc.董事会成员，Zeltiq，Inc.于2013年至2017年担任首席董事，于2004年至2010年担任Intuitive Surgical，Inc.董事，Kyphon Inc.于2007年担任董事，并在多个私人董事会任职。Grossman先生拥有俄亥俄州立大学动物科学学士学位和美国佩珀代因大学佩珀代因格拉齐亚迪奥商学院金融工商管理硕士学位。
D. Keith Grossman,has served as Lead Independent Director since February 2022 and served as Chairman of Board from April 2014 to February 2022. Mr. Grossman served as Chairman of the board of directors of Nevro Corp. ("Nevro"), a global medical device company, from March 2019 through April 2025 when the company was acquired by Globus Medical, Inc., previously serving as Nevro's Chief Executive Officer from March 2019 to April 2023 and Executive Chairman from April 2023 to October 2023. Mr. Grossman has also served as Vice Chairman of Alcon Inc., an eye care products company, since April 2019. Previously, he was Chief Executive Officer and President of Thoratec, a medical device company, from September 2014 to December 2015 and from January 1996 to January 2006; Chief Executive Officer and President of Conceptus, a manufacturer and developer of medical devices, from December 2011 to June 2013; and Managing Director for TPG, a private equity firm, from September 2007 to December 2011. He also previously held positions with Eon Labs, a pharmaceutical company, SulzerMedica, a manufacturer of implantable medical devices, and American Hospital Supply/McGaw Labs, a medical supply company. Mr. Grossman served on the board of directors of ViewRay, a medical device company in the field of cancer therapy, from July 2018 to February 2021; Zeltiq (acquired by Allergan), a company that markets and licenses devices Outset Medical, Inc. ed for cryolipolysis procedures, from October 2013 to May 2017; Kyphon (acquired by Medtronic plc), a medical device company, from May 2007 to November 2007; Intuitive Surgical, a medical device company, from April 2003 to April 2010; and Tandem Diabetes Care, a medical device company, from April 2010 to January 2012. Mr. Grossman has also served on the board of directors of a number of private companies. Mr. Grossman holds a B.S. from Ohio State University and an M.B.A. from the George L. Graziadio School of Business and Management, Pepperdine University. - D. Keith Grossman，在医疗器械和用品领域拥有超过35年的经验，包括担任医疗保健上市公司的首席执行官。他自2019年3月起担任Nevro的董事长、首席执行官兼总裁。他还自2014年起担任Outset Medical董事会主席。他于1996年至2006年以及2014年至2015年担任Thoratec Corporation的总裁兼首席执行官，并于1996年至2015年担任董事会成员。Grossman先生曾于2011年至2013年担任Conceptus公司的首席执行官和董事会成员。2007年至2011年担任TPG资本有限公司董事总经理兼高级顾问。Grossman先生还曾于2018年至2021年担任ViewRay，Inc.董事会成员，Zeltiq，Inc.于2013年至2017年担任首席董事，于2004年至2010年担任Intuitive Surgical，Inc.董事，Kyphon Inc.于2007年担任董事，并在多个私人董事会任职。Grossman先生拥有俄亥俄州立大学动物科学学士学位和美国佩珀代因大学佩珀代因格拉齐亚迪奥商学院金融工商管理硕士学位。
- D. Keith Grossman,has served as Lead Independent Director since February 2022 and served as Chairman of Board from April 2014 to February 2022. Mr. Grossman served as Chairman of the board of directors of Nevro Corp. ("Nevro"), a global medical device company, from March 2019 through April 2025 when the company was acquired by Globus Medical, Inc., previously serving as Nevro's Chief Executive Officer from March 2019 to April 2023 and Executive Chairman from April 2023 to October 2023. Mr. Grossman has also served as Vice Chairman of Alcon Inc., an eye care products company, since April 2019. Previously, he was Chief Executive Officer and President of Thoratec, a medical device company, from September 2014 to December 2015 and from January 1996 to January 2006; Chief Executive Officer and President of Conceptus, a manufacturer and developer of medical devices, from December 2011 to June 2013; and Managing Director for TPG, a private equity firm, from September 2007 to December 2011. He also previously held positions with Eon Labs, a pharmaceutical company, SulzerMedica, a manufacturer of implantable medical devices, and American Hospital Supply/McGaw Labs, a medical supply company. Mr. Grossman served on the board of directors of ViewRay, a medical device company in the field of cancer therapy, from July 2018 to February 2021; Zeltiq (acquired by Allergan), a company that markets and licenses devices Outset Medical, Inc. ed for cryolipolysis procedures, from October 2013 to May 2017; Kyphon (acquired by Medtronic plc), a medical device company, from May 2007 to November 2007; Intuitive Surgical, a medical device company, from April 2003 to April 2010; and Tandem Diabetes Care, a medical device company, from April 2010 to January 2012. Mr. Grossman has also served on the board of directors of a number of private companies. Mr. Grossman holds a B.S. from Ohio State University and an M.B.A. from the George L. Graziadio School of Business and Management, Pepperdine University.
- Karen Drexler
-
Karen Drexler，自2021年1月起任职。Drexler女士自2017年11月起担任医疗器械公司ResMed Inc.的董事会成员，自2021年10月起担任心脏起搏公司EBR Systems，Inc.的董事会成员。她目前还在两家私营公司的董事会任职：肺部智能解决方案和分析公司VIDA Health和人工智能公司HUMA.AI。德雷克斯勒女士此前曾于2016年6月至2020年7月担任Sandstone Diagnostics，Inc.的首席执行官，该公司是一家开发用于即时医疗检测的仪器和耗材的私营公司。她于2019年8月至2024年9月担任生物电子医药公司Tivic Health Systems, Inc.的董事会成员，并于2011年至2017年担任私营数字胰岛素治疗公司Hygieia，Inc.的董事会主席。德雷克斯勒女士还曾在诊断、医疗设备和数字健康领域的多家私营公司的董事会任职。德雷克斯勒女士是Amira Medical Inc.的创始人、总裁和首席执行官，该公司是一家专注于血糖监测技术的私营公司，从1996年到2001年被出售给罗氏控股公司。在此之前，她曾在医疗器械公司LifeScan担任管理职务，包括领导其制造职能，并在其出售给强生的过程中发挥了关键作用。德雷克斯勒女士也是G100网络和斯坦福女性董事会的成员。Drexler女士拥有普林斯顿大学的理学学士学位和斯坦福大学商学院的工商管理硕士学位。
Karen Drexler,has served on Board since January 2021. Ms. Drexler has served on the board of directors of ResMed Inc., a medical device company, since November 2017, and on the board of directors of EBR Systems, Inc., a cardiac pacing company, since October 2021. She also currently serves on the boards of directors of two private companies: VIDA Health, a lung intelligence solutions and analytics company and Huma.AI, a healthcare artificial intelligence company. Ms. Drexler previously served as CEO of Sandstone Diagnostics, Inc., a private company developing instruments and consumables for point-of-care medical testing, from June 2016 until July 2020. She served on the board of directors of Tivic Health Systems, Inc., a bioelectronic medicine company, from August 2019 to September 2024, and as chair of the board of Hygieia, Inc., a private digital insulin therapy company, from 2011 to 2017. Ms. Drexler has also served on the board of directors of a number of private companies in the fields of diagnostics, medical devices, and digital health. Ms. Drexler was founder, president, and CEO of Amira Medical Inc., a private company focused on glucose monitoring technology, from 1996 until it was sold to Roche Holding AG in 2001. Prior to that, she held management roles at LifeScan, a medical device company, including leading its manufacturing function, and played a key role in its sale to Johnson & Johnson. Ms. Drexler is also a member of the G100 Network and Stanford Women on Boards. Ms. Drexler holds a B.S.E. from Princeton University and an M.B.A. from the Stanford University Graduate School of Business. - Karen Drexler，自2021年1月起任职。Drexler女士自2017年11月起担任医疗器械公司ResMed Inc.的董事会成员，自2021年10月起担任心脏起搏公司EBR Systems，Inc.的董事会成员。她目前还在两家私营公司的董事会任职：肺部智能解决方案和分析公司VIDA Health和人工智能公司HUMA.AI。德雷克斯勒女士此前曾于2016年6月至2020年7月担任Sandstone Diagnostics，Inc.的首席执行官，该公司是一家开发用于即时医疗检测的仪器和耗材的私营公司。她于2019年8月至2024年9月担任生物电子医药公司Tivic Health Systems, Inc.的董事会成员，并于2011年至2017年担任私营数字胰岛素治疗公司Hygieia，Inc.的董事会主席。德雷克斯勒女士还曾在诊断、医疗设备和数字健康领域的多家私营公司的董事会任职。德雷克斯勒女士是Amira Medical Inc.的创始人、总裁和首席执行官，该公司是一家专注于血糖监测技术的私营公司，从1996年到2001年被出售给罗氏控股公司。在此之前，她曾在医疗器械公司LifeScan担任管理职务，包括领导其制造职能，并在其出售给强生的过程中发挥了关键作用。德雷克斯勒女士也是G100网络和斯坦福女性董事会的成员。Drexler女士拥有普林斯顿大学的理学学士学位和斯坦福大学商学院的工商管理硕士学位。
- Karen Drexler,has served on Board since January 2021. Ms. Drexler has served on the board of directors of ResMed Inc., a medical device company, since November 2017, and on the board of directors of EBR Systems, Inc., a cardiac pacing company, since October 2021. She also currently serves on the boards of directors of two private companies: VIDA Health, a lung intelligence solutions and analytics company and Huma.AI, a healthcare artificial intelligence company. Ms. Drexler previously served as CEO of Sandstone Diagnostics, Inc., a private company developing instruments and consumables for point-of-care medical testing, from June 2016 until July 2020. She served on the board of directors of Tivic Health Systems, Inc., a bioelectronic medicine company, from August 2019 to September 2024, and as chair of the board of Hygieia, Inc., a private digital insulin therapy company, from 2011 to 2017. Ms. Drexler has also served on the board of directors of a number of private companies in the fields of diagnostics, medical devices, and digital health. Ms. Drexler was founder, president, and CEO of Amira Medical Inc., a private company focused on glucose monitoring technology, from 1996 until it was sold to Roche Holding AG in 2001. Prior to that, she held management roles at LifeScan, a medical device company, including leading its manufacturing function, and played a key role in its sale to Johnson & Johnson. Ms. Drexler is also a member of the G100 Network and Stanford Women on Boards. Ms. Drexler holds a B.S.E. from Princeton University and an M.B.A. from the Stanford University Graduate School of Business.
高管简历
中英对照 | 中文 | 英文- Leslie Trigg
Leslie Trigg已经同意在我们的董事会任职。Trigg女士自2014年11月起担任Except Medical Inc.“；Except”；（NASDAQ:OM）的总裁兼首席执行官。从2012年3月到2014年3月，她加入Warburg Pincus公司（私人股本公司），在那里她曾担任高级管理人员。在此之前，2010年1月至2012年2月，特里格曾在医疗设备公司Lutonix（被CR Bard收购）担任多个职位，最近的职位是担任执行Vice President，并担任医疗设备公司AccessClosure（被Cardinal Health收购）的首席商务官，从2006年9月到2009年6月。她此前也曾担任FoxHollow Technologies公司（被EV3/Covidien公司收购）（治疗外周动脉疾病的设备制造商）、Cytyc公司（诊断和医疗设备公司）、Pro-Ducture Health公司（被Cytyc公司收购）（医疗设备公司）、Guidant公司（心血管医疗设备公司）的职务。Trigg女士拥有西北大学（Northwestern University）的学士学位和加州大学伯克利分校哈斯商学院（Haas School of Business，UC Berkeley）的工商管理硕士学位。
Leslie Trigg,has served as President and CEO and a member of Board since November 2014 and as Chair of Board since February 2022. Ms. Trigg joined the Company from Warburg Pincus, a private equity firm, where she was an Executive in Residence from March 2012 to March 2014. Prior to that, Ms. Trigg served in several roles at Lutonix (acquired by CR Bard), a medical device company, from January 2010 to February 2012, most recently as Executive Vice President, and as Chief Business Officer of AccessClosure (acquired by Cardinal Health), a medical device company, from September 2006 to June 2009. She also previously held positions with FoxHollow Technologies (acquired by ev3/Covidien), a manufacturer of devices to treat peripheral artery disease, Cytyc, a diagnostic and medical device company, Pro-Duct Health (acquired by Cytyc), a medical device company, and Guidant, a cardiovascular medical device company. Ms. Trigg also serves as the Chair of the board of directors of the Medical Device Manufacturers Association (MDMA). Previously, Ms. Trigg served on the boards of directors of Adaptive Biotechnologies Corporation, a biotechnology company, from March 2021 to June 2023, and of ARYA Sciences Acquisition Corp IV, a special purpose acquisition company, from March 2021 to July 2024. Ms. Trigg holds a B.S. degree from Northwestern University and an M.B.A. from The Haas School of Business, University of California, Berkeley.- Leslie Trigg已经同意在我们的董事会任职。Trigg女士自2014年11月起担任Except Medical Inc.“；Except”；（NASDAQ:OM）的总裁兼首席执行官。从2012年3月到2014年3月，她加入Warburg Pincus公司（私人股本公司），在那里她曾担任高级管理人员。在此之前，2010年1月至2012年2月，特里格曾在医疗设备公司Lutonix（被CR Bard收购）担任多个职位，最近的职位是担任执行Vice President，并担任医疗设备公司AccessClosure（被Cardinal Health收购）的首席商务官，从2006年9月到2009年6月。她此前也曾担任FoxHollow Technologies公司（被EV3/Covidien公司收购）（治疗外周动脉疾病的设备制造商）、Cytyc公司（诊断和医疗设备公司）、Pro-Ducture Health公司（被Cytyc公司收购）（医疗设备公司）、Guidant公司（心血管医疗设备公司）的职务。Trigg女士拥有西北大学（Northwestern University）的学士学位和加州大学伯克利分校哈斯商学院（Haas School of Business，UC Berkeley）的工商管理硕士学位。
- Leslie Trigg,has served as President and CEO and a member of Board since November 2014 and as Chair of Board since February 2022. Ms. Trigg joined the Company from Warburg Pincus, a private equity firm, where she was an Executive in Residence from March 2012 to March 2014. Prior to that, Ms. Trigg served in several roles at Lutonix (acquired by CR Bard), a medical device company, from January 2010 to February 2012, most recently as Executive Vice President, and as Chief Business Officer of AccessClosure (acquired by Cardinal Health), a medical device company, from September 2006 to June 2009. She also previously held positions with FoxHollow Technologies (acquired by ev3/Covidien), a manufacturer of devices to treat peripheral artery disease, Cytyc, a diagnostic and medical device company, Pro-Duct Health (acquired by Cytyc), a medical device company, and Guidant, a cardiovascular medical device company. Ms. Trigg also serves as the Chair of the board of directors of the Medical Device Manufacturers Association (MDMA). Previously, Ms. Trigg served on the boards of directors of Adaptive Biotechnologies Corporation, a biotechnology company, from March 2021 to June 2023, and of ARYA Sciences Acquisition Corp IV, a special purpose acquisition company, from March 2021 to July 2024. Ms. Trigg holds a B.S. degree from Northwestern University and an M.B.A. from The Haas School of Business, University of California, Berkeley.
- John L. Brottem
John L.Brottem自2020年5月起担任我们的总法律顾问。在加入该公司之前，布罗特姆曾在Omnicell，Inc.担任多个职位，该公司是一家为梦百合系统和药房提供药物管理自动化解决方案和坚持工具的领先供应商，他曾于2019年9月至2020年5月担任Vice President、法律顾问和副总法律顾问，并担任Vice President，2016年4月至2019年9月担任法律和副总法律顾问；2011年11月至2016年4月担任高级总监，法律和副总法律顾问。在加入Omnicell之前，Brottem先生于2009年1月至2011年11月担任网络解决方案公司Brocade CommunicationsSystems，Inc.的公司法律顾问，于2008年2月至2009年1月担任网络解决方案公司Foundry Networks，Inc.的公司法律顾问，并担任Cooley Godward Kronish LLP的律师，一家国际律师事务所，2001年11月至2008年2月。Brottem先生拥有西方学院（Occidental College）的学士学位和加州大学戴维斯分校（University of California，Davis，School of Law）的法学博士学位。
John L. Brottem,has served as General Counsel and Secretary since May 2020. Prior to joining the Company, Mr. Brottem served in a number of roles at Omnicell, Inc., a leading provider of medication management automation solutions and adherence tools for healthcare systems and pharmacies: as Vice President, Legal and Deputy General Counsel from September 2019 to May 2020 as Vice President, Legal and Associate General Counsel from April 2016 to September 2019 and Senior Director, Legal and Associate General Counsel from November 2011 to April 2016. Prior to Omnicell, Mr. Brottem was Corporate Counsel at Brocade Communications Systems, Inc., a networking solutions company, from January 2009 to November 2011 Corporate Counsel at Foundry Networks, Inc., a networking solutions company, from February 2008 to January 2009 and Associate at Cooley Godward Kronish LLP, an international law firm, from November 2001 to February 2008. Mr. Brottem holds a B.A. from Occidental College and a J.D. from the University of California, Davis, School of Law.- John L.Brottem自2020年5月起担任我们的总法律顾问。在加入该公司之前，布罗特姆曾在Omnicell，Inc.担任多个职位，该公司是一家为梦百合系统和药房提供药物管理自动化解决方案和坚持工具的领先供应商，他曾于2019年9月至2020年5月担任Vice President、法律顾问和副总法律顾问，并担任Vice President，2016年4月至2019年9月担任法律和副总法律顾问；2011年11月至2016年4月担任高级总监，法律和副总法律顾问。在加入Omnicell之前，Brottem先生于2009年1月至2011年11月担任网络解决方案公司Brocade CommunicationsSystems，Inc.的公司法律顾问，于2008年2月至2009年1月担任网络解决方案公司Foundry Networks，Inc.的公司法律顾问，并担任Cooley Godward Kronish LLP的律师，一家国际律师事务所，2001年11月至2008年2月。Brottem先生拥有西方学院（Occidental College）的学士学位和加州大学戴维斯分校（University of California，Davis，School of Law）的法学博士学位。
- John L. Brottem,has served as General Counsel and Secretary since May 2020. Prior to joining the Company, Mr. Brottem served in a number of roles at Omnicell, Inc., a leading provider of medication management automation solutions and adherence tools for healthcare systems and pharmacies: as Vice President, Legal and Deputy General Counsel from September 2019 to May 2020 as Vice President, Legal and Associate General Counsel from April 2016 to September 2019 and Senior Director, Legal and Associate General Counsel from November 2011 to April 2016. Prior to Omnicell, Mr. Brottem was Corporate Counsel at Brocade Communications Systems, Inc., a networking solutions company, from January 2009 to November 2011 Corporate Counsel at Foundry Networks, Inc., a networking solutions company, from February 2008 to January 2009 and Associate at Cooley Godward Kronish LLP, an international law firm, from November 2001 to February 2008. Mr. Brottem holds a B.A. from Occidental College and a J.D. from the University of California, Davis, School of Law.
- Renee Gaeta
Renee Gaeta，自2022年8月起担任Candel董事会成员。Gaeta女士目前是Eko Devices，Inc.的首席财务官，Eko Devices，Inc.是一家专注于心肺数字健康解决方案的私营公司，自2021年7月起担任该职位。在此之前的2017年7月至2021年7月，Gaeta女士是Establishment Labs控股公司的首席财务官，该公司是一家上市的全球性医疗设备公司，专注于美容技术。2014年8月至2017年6月，Gaeta女士担任Sientra, Inc.副总裁兼公司财务总监，该公司是一家上市的全球医疗美容公司，她是该公司执行团队的成员，并领导财务部门。2004年至2014年，加埃塔在毕马威、LLP或毕马威工作。Gaeta女士曾在毕马威担任多个职位，最近担任交易和重组小组的咨询主任。Gaeta女士还担任SeaSpine控股公司董事，直至2023年1月（纳斯达克：SPNE），从2019年2月至2023年1月，该公司被Orthofix Medical Inc.（纳斯达克：OFIX）收购。Gaeta女士以优异成绩获得了洛约拉玛丽蒙特大学会计学学士学位，是加利福尼亚州的注册会计师。
Renee Gaeta,has served as a member of Candel's board of directors since August 2022. Ms. Gaeta currently is Chief Financial Officer of Eko Devices, Inc., a private company focused on cardiopulmonary digital health solutions, a position she has held since July 2021. Prior to that, from July 2017 to July 2021, Ms. Gaeta was Chief Financial Officer at Establishment Labs Holdings, Inc., a publicly traded global medical device company focused on aesthetic technologies. From August 2014 to June 2017, Ms. Gaeta was Vice President and Corporate Controller at Sientra, Inc., a publicly traded global medical aesthetics company, where she was a member of the executive team and headed the finance department. From 2004 to 2014, Ms. Gaeta worked at KPMG, LLP, or KPMG. Ms. Gaeta held various positions at KPMG, most recently as an Advisory Director in the Transactions and Restructuring Group. Ms. Gaeta also served as a director of SeaSpine Holdings Corp until January 2023 (Nasdaq: SPNE) from February 2019 until January 2023, when it was acquired by Orthofix Medical Inc. (Nasdaq: OFIX). Ms. Gaeta received her B.S., cum laude, in Accounting from Loyola Marymount University and is a Certified Public Accountant in the State of California.- Renee Gaeta，自2022年8月起担任Candel董事会成员。Gaeta女士目前是Eko Devices，Inc.的首席财务官，Eko Devices，Inc.是一家专注于心肺数字健康解决方案的私营公司，自2021年7月起担任该职位。在此之前的2017年7月至2021年7月，Gaeta女士是Establishment Labs控股公司的首席财务官，该公司是一家上市的全球性医疗设备公司，专注于美容技术。2014年8月至2017年6月，Gaeta女士担任Sientra, Inc.副总裁兼公司财务总监，该公司是一家上市的全球医疗美容公司，她是该公司执行团队的成员，并领导财务部门。2004年至2014年，加埃塔在毕马威、LLP或毕马威工作。Gaeta女士曾在毕马威担任多个职位，最近担任交易和重组小组的咨询主任。Gaeta女士还担任SeaSpine控股公司董事，直至2023年1月（纳斯达克：SPNE），从2019年2月至2023年1月，该公司被Orthofix Medical Inc.（纳斯达克：OFIX）收购。Gaeta女士以优异成绩获得了洛约拉玛丽蒙特大学会计学学士学位，是加利福尼亚州的注册会计师。
- Renee Gaeta,has served as a member of Candel's board of directors since August 2022. Ms. Gaeta currently is Chief Financial Officer of Eko Devices, Inc., a private company focused on cardiopulmonary digital health solutions, a position she has held since July 2021. Prior to that, from July 2017 to July 2021, Ms. Gaeta was Chief Financial Officer at Establishment Labs Holdings, Inc., a publicly traded global medical device company focused on aesthetic technologies. From August 2014 to June 2017, Ms. Gaeta was Vice President and Corporate Controller at Sientra, Inc., a publicly traded global medical aesthetics company, where she was a member of the executive team and headed the finance department. From 2004 to 2014, Ms. Gaeta worked at KPMG, LLP, or KPMG. Ms. Gaeta held various positions at KPMG, most recently as an Advisory Director in the Transactions and Restructuring Group. Ms. Gaeta also served as a director of SeaSpine Holdings Corp until January 2023 (Nasdaq: SPNE) from February 2019 until January 2023, when it was acquired by Orthofix Medical Inc. (Nasdaq: OFIX). Ms. Gaeta received her B.S., cum laude, in Accounting from Loyola Marymount University and is a Certified Public Accountant in the State of California.
- Marc Nash
Marc Nash，自2023年7月起担任运营和研发高级副总裁。纳什先生于2019年12月加入公司，担任运营高级总监，并于2021年3月被任命为制造副总裁。在加入公司之前，从2016年6月到2019年6月，纳什先生担任医疗技术公司Epocal Inc.的运营总监（也是被Siemens Healthineers收购的Alere，Inc.的子公司），在此期间，他负责即时诊断产品和平台的端到端制造业务。从2012年到2016年，Nash先生在医疗技术公司Alere Inc.担任过越来越多的职务，负责在全球范围内转让、巩固和加强II类和III类即时护理和快速诊断产品。纳什先生拥有联合学院的学士学位和以色列海法大学的工商管理硕士学位。
Marc Nash,has served as Senior Vice President, Operations and R&D since July 2023. Mr. Nash joined the Company in December 2019 as Senior Director of Operations and was named Vice President, Manufacturing in March 2021. Prior to joining the Company, from June 2016 through June 2019, Mr. Nash served as Director of Operations at Epocal Inc., a medical technology company (and a subsidiary of Alere, Inc. acquired by Siemens Healthineers), during which time he was responsible for the end-to-end manufacturing operations of point of care diagnostics products and platforms. From 2012 through 2016, Mr. Nash held various positions of increasing responsibility at Alere Inc., a medical technology company, where he was responsible for the transfer, consolidation and enhancement of class II and class III point of care and rapid diagnostic products globally. Mr. Nash holds a B.S. from Union College and an M.B.A. from the University of Haifa, Israel.- Marc Nash，自2023年7月起担任运营和研发高级副总裁。纳什先生于2019年12月加入公司，担任运营高级总监，并于2021年3月被任命为制造副总裁。在加入公司之前，从2016年6月到2019年6月，纳什先生担任医疗技术公司Epocal Inc.的运营总监（也是被Siemens Healthineers收购的Alere，Inc.的子公司），在此期间，他负责即时诊断产品和平台的端到端制造业务。从2012年到2016年，Nash先生在医疗技术公司Alere Inc.担任过越来越多的职务，负责在全球范围内转让、巩固和加强II类和III类即时护理和快速诊断产品。纳什先生拥有联合学院的学士学位和以色列海法大学的工商管理硕士学位。
- Marc Nash,has served as Senior Vice President, Operations and R&D since July 2023. Mr. Nash joined the Company in December 2019 as Senior Director of Operations and was named Vice President, Manufacturing in March 2021. Prior to joining the Company, from June 2016 through June 2019, Mr. Nash served as Director of Operations at Epocal Inc., a medical technology company (and a subsidiary of Alere, Inc. acquired by Siemens Healthineers), during which time he was responsible for the end-to-end manufacturing operations of point of care diagnostics products and platforms. From 2012 through 2016, Mr. Nash held various positions of increasing responsibility at Alere Inc., a medical technology company, where he was responsible for the transfer, consolidation and enhancement of class II and class III point of care and rapid diagnostic products globally. Mr. Nash holds a B.S. from Union College and an M.B.A. from the University of Haifa, Israel.
- Renee Gaeta
Renee Gaeta，于2024年2月至2024年5月被强生收购期间，在医疗器械公司ShockWave Medical, Inc.中担任首席财务官的TERM1之职。在此之前，她于2021年7月至2024年2月担任心肺数字健康公司Eko Health的首席财务官。2017年7月至2021年7月，Gaeta女士在全球医疗技术公司Establishment Labs控股公司担任首席财务官；2014年8月至2017年6月，她在医疗美容公司Sientra, Inc.担任副总裁兼公司财务总监。在她职业生涯的早期，加埃塔女士在毕马威会计师事务所工作了十年，在那里她担任过各种职责日益增加的职位。Gaeta女士自2022年8月起担任生物制药公司Candel Therapeutics, Inc.的董事会成员。此前，她还曾在2019年2月至2023年1月与Orthofix Medical合并的全球医疗技术公司SeaSpine控股公司的董事会任职。Gaeta女士拥有Loyola Marymount大学的学士学位，是加利福尼亚州的注册会计师。
Renee Gaeta,served as the Chief Financial Officer of Shockwave Medical, Inc., a medical device company, from February 2024 until it was acquired by Johnson & Johnson in May 2024. Prior to that, she served as Chief Financial Officer of Eko Health, a cardiopulmonary digital health company, from July 2021 to February 2024. From July 2017 to July 2021, Ms. Gaeta was Chief Financial Officer at Establishment Labs Holdings, Inc., a global medical technology company, and from August 2014 to June 2017, she served as Vice President, Corporate Controller at Sientra, Inc., a medical aesthetics company. Earlier in her career, Ms. Gaeta spent ten years at KPMG LLP where she held various positions of increasing responsibility. Ms. Gaeta has served on the board of directors of Candel Therapeutics, Inc., a biopharmaceutical company, since August 2022. Previously, she also served on the board of directors of SeaSpine Holdings Corporation, a global medical technology company, from February 2019 to January 2023 when it merged with Orthofix Medical. Ms. Gaeta holds a B.S. from Loyola Marymount University and is a Certified Public Accountant in the State of California.- Renee Gaeta，于2024年2月至2024年5月被强生收购期间，在医疗器械公司ShockWave Medical, Inc.中担任首席财务官的TERM1之职。在此之前，她于2021年7月至2024年2月担任心肺数字健康公司Eko Health的首席财务官。2017年7月至2021年7月，Gaeta女士在全球医疗技术公司Establishment Labs控股公司担任首席财务官；2014年8月至2017年6月，她在医疗美容公司Sientra, Inc.担任副总裁兼公司财务总监。在她职业生涯的早期，加埃塔女士在毕马威会计师事务所工作了十年，在那里她担任过各种职责日益增加的职位。Gaeta女士自2022年8月起担任生物制药公司Candel Therapeutics, Inc.的董事会成员。此前，她还曾在2019年2月至2023年1月与Orthofix Medical合并的全球医疗技术公司SeaSpine控股公司的董事会任职。Gaeta女士拥有Loyola Marymount大学的学士学位，是加利福尼亚州的注册会计师。
- Renee Gaeta,served as the Chief Financial Officer of Shockwave Medical, Inc., a medical device company, from February 2024 until it was acquired by Johnson & Johnson in May 2024. Prior to that, she served as Chief Financial Officer of Eko Health, a cardiopulmonary digital health company, from July 2021 to February 2024. From July 2017 to July 2021, Ms. Gaeta was Chief Financial Officer at Establishment Labs Holdings, Inc., a global medical technology company, and from August 2014 to June 2017, she served as Vice President, Corporate Controller at Sientra, Inc., a medical aesthetics company. Earlier in her career, Ms. Gaeta spent ten years at KPMG LLP where she held various positions of increasing responsibility. Ms. Gaeta has served on the board of directors of Candel Therapeutics, Inc., a biopharmaceutical company, since August 2022. Previously, she also served on the board of directors of SeaSpine Holdings Corporation, a global medical technology company, from February 2019 to January 2023 when it merged with Orthofix Medical. Ms. Gaeta holds a B.S. from Loyola Marymount University and is a Certified Public Accountant in the State of California.